头颈部癌中的极光激酶。
Aurora kinases in head and neck cancer.
机构信息
Program in Developmental Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
出版信息
Lancet Oncol. 2013 Sep;14(10):e425-35. doi: 10.1016/S1470-2045(13)70128-1.
Abstract
In healthy cells, controlled activation of aurora kinases regulates mitosis. Overexpression and hyperactivation of aurora kinases A and B have major roles in tumorigenesis, and can induce aneuploidy and genomic instability. In squamous-cell carcinomas of the head and neck, overexpression of aurora kinase A is associated with decreased survival, and a reduction in aurora kinase A and aurora kinase B expression inhibits cell growth and increases apoptosis. In this Review, we provide an overview of the biological functions of aurora kinases in healthy cells and in cancer cells, and we review small studies and high-throughput datasets that particularly implicate aurora kinase A in the pathogenesis of squamous-cell carcinomas of the head and neck. Early phase trials are beginning to assess the activity of small-molecule inhibitors of aurora kinases. We summarise trials of aurora kinase inhibitors in squamous-cell carcinomas of the head and neck, and discuss directions for future drug combination trials and biomarkers to use with drugs that inhibit aurora kinases.
摘要
在健康细胞中，极光激酶的受控激活调节有丝分裂。极光激酶 A 和 B 的过表达和过度激活在肿瘤发生中起主要作用，并可诱导非整倍体和基因组不稳定性。在头颈部鳞状细胞癌中，极光激酶 A 的过表达与生存率降低有关，而降低极光激酶 A 和极光激酶 B 的表达可抑制细胞生长并增加细胞凋亡。在这篇综述中，我们概述了极光激酶在健康细胞和癌细胞中的生物学功能，并回顾了特别表明极光激酶 A 参与头颈部鳞状细胞癌发病机制的小型研究和高通量数据集。早期阶段的试验开始评估小分子极光激酶抑制剂的活性。我们总结了头颈部鳞状细胞癌中极光激酶抑制剂的试验，并讨论了未来药物联合试验和使用抑制极光激酶的药物的生物标志物的方向。
相似文献
1
Aurora kinases in head and neck cancer.头颈部癌中的极光激酶。
Lancet Oncol. 2013 Sep;14(10):e425-35. doi: 10.1016/S1470-2045(13)70128-1.
2
Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck.极光激酶抑制可克服头颈部鳞状细胞癌对西妥昔单抗的耐药性。
Oncotarget. 2011 Aug;2(8):599-609. doi: 10.18632/oncotarget.311.
3
Aurora Kinase Inhibitors in Head and Neck Cancer.头颈部癌的 Aurora 激酶抑制剂。
Curr Top Med Chem. 2018;18(3):199-213. doi: 10.2174/1568026618666180112163741.
4
Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.极光激酶A抑制与紫杉醇联合作为头颈部鳞状细胞癌的靶向联合治疗
Head Neck. 2009 May;31(5):625-34. doi: 10.1002/hed.21007.
5
The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism.头颈部鳞状细胞癌对西妥昔单抗治疗的反应取决于极光激酶A多态性。
Oncotarget. 2014 Jul 30;5(14):5428-38. doi: 10.18632/oncotarget.2117.
6
Aurora B: a new prognostic marker and therapeutic target in cancer.极光 B：癌症的一个新预后标志物和治疗靶点。
Curr Med Chem. 2011;18(4):482-96. doi: 10.2174/092986711794480203.
7
Aurora Kinases as Therapeutic Targets in Head and Neck Cancer.极光激酶在头颈部癌症中的治疗靶点。
Cancer J. 2022;28(5):387-400. doi: 10.1097/PPO.0000000000000614.
8
Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B.核 Survivin 表达与 Aurora-B 共同与头颈部癌症的恶性行为相关。
Oral Oncol. 2010 Apr;46(4):263-70. doi: 10.1016/j.oraloncology.2010.01.004. Epub 2010 Feb 6.
9
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.LIM蛋白AJUBA的突变介导头颈部鳞状细胞癌对细胞周期抑制剂治疗的敏感性。
Cancer Lett. 2017 Apr 28;392:71-82. doi: 10.1016/j.canlet.2017.01.024. Epub 2017 Jan 23.
10
Shared and separate functions of polo-like kinases and aurora kinases in cancer.Polo-like 激酶和 Aurora 激酶在癌症中的共同和独立功能。
Nat Rev Cancer. 2010 Dec;10(12):825-41. doi: 10.1038/nrc2964. Epub 2010 Nov 24.
引用本文的文献
1
, and pseudogenes: molecular role in development and progression of head and neck squamous cell carcinomas and their diagnostic utility.以及假基因：在头颈部鳞状细胞癌的发生发展中的分子作用及其诊断效用。
Rep Pract Oncol Radiother. 2025 Feb 19;29(6):718-731. doi: 10.5603/rpor.104016. eCollection 2024.
2
EMILIN-1 Suppresses Cell Proliferation through Altered Cell Cycle Regulation in Head and Neck Squamous Cell Carcinoma.埃米林-1通过改变细胞周期调控抑制头颈部鳞状细胞癌的细胞增殖。
Am J Pathol. 2025 May;195(5):995-1012. doi: 10.1016/j.ajpath.2025.01.010. Epub 2025 Jan 30.
3
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.极光激酶A抑制剂阿利西替尼与帕博利珠单抗治疗难治性、Rb基因缺陷型头颈部鳞状细胞癌的I/II期研究
Clin Cancer Res. 2025 Feb 3;31(3):479-490. doi: 10.1158/1078-0432.CCR-24-2290.
4
The genes regulating sensitivity of tumor cells to T cell-mediated killing: could they be potential personalized immunotherapeutic targets in head and neck squamous cell carcinoma?调节肿瘤细胞对T细胞介导杀伤敏感性的基因：它们能否成为头颈部鳞状细胞癌潜在的个性化免疫治疗靶点？
Discov Oncol. 2023 Nov 5;14(1):199. doi: 10.1007/s12672-023-00806-z.
5
Development and Validation of a Novel Diagnostic Nomogram Model Using Serum Oxidative Stress Markers and AURKA for Prediction of Nasopharyngeal Carcinoma.使用血清氧化应激标志物和极光激酶A（AURKA）预测鼻咽癌的新型诊断列线图模型的开发与验证
Cancer Manag Res. 2023 Sep 27;15:1053-1062. doi: 10.2147/CMAR.S402572. eCollection 2023.
6
CHD1, a multifaceted epigenetic remodeler in prostate cancer.CHD1，一种在前列腺癌中具有多方面作用的表观遗传重塑因子。
Front Oncol. 2023 Jan 26;13:1123362. doi: 10.3389/fonc.2023.1123362. eCollection 2023.
7
CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2.CHD1 通过抑制 AURKA 与其共激活因子 TPX2 的相互作用来提高对 Aurora 激酶抑制剂的敏感性。
Cancer Res. 2022 Sep 2;82(17):3088-3101. doi: 10.1158/0008-5472.CAN-22-0631.
8
Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance.与治疗耐药相关的口腔癌主要分子信号通路
Front Oral Health. 2021 Jan 25;1:603160. doi: 10.3389/froh.2020.603160. eCollection 2020.
9
Targeting pan-essential genes in cancer: Challenges and opportunities.靶向癌症中的泛必需基因：挑战与机遇。
Cancer Cell. 2021 Apr 12;39(4):466-479. doi: 10.1016/j.ccell.2020.12.008. Epub 2021 Jan 14.
10
TAp63-miRNA-AURKA Axis as a Therapeutic Target for Cutaneous Squamous Cell Carcinoma.TAp63-miRNA-AURKA 轴作为皮肤鳞状细胞癌的治疗靶点。
Cancer Res. 2020 Jun 15;80(12):2439-2440. doi: 10.1158/0008-5472.CAN-20-1215.
本文引用的文献
1
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.帕唑帕尼增强紫杉醇诱导的间变性甲状腺癌有丝分裂灾难。
Sci Transl Med. 2013 Jan 2;5(166):166ra3. doi: 10.1126/scitranslmed.3004358.
2
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.表皮生长因子受体表达对头颈部和结直肠癌一线化疗联合西妥昔单抗的预测价值：EXTREME 和 CRYSTAL 研究数据的分析。
Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19.
3
Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer.BMI1-AURKA 信号调节的染色体不稳定性驱动头颈部癌症的进展。
Cancer Res. 2013 Jan 15;73(2):953-66. doi: 10.1158/0008-5472.CAN-12-2397. Epub 2012 Nov 30.
4
The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.alisertib（一种研究中的 Aurora 激酶 A 抑制剂）与多西他赛联合应用可促进上胃肠道腺癌的临床前细胞模型中的细胞死亡并抑制肿瘤生长。
Cancer. 2013 Feb 15;119(4):904-14. doi: 10.1002/cncr.27801. Epub 2012 Sep 12.
5
Aurora A kinase (AURKA) in normal and pathological cell division.极光激酶 A（AURKA）在正常和病理细胞分裂中的作用。
Cell Mol Life Sci. 2013 Feb;70(4):661-87. doi: 10.1007/s00018-012-1073-7. Epub 2012 Aug 3.
6
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.多机构帕唑帕尼单药治疗晚期间变性甲状腺癌的 2 期临床试验。
J Clin Endocrinol Metab. 2012 Sep;97(9):3179-84. doi: 10.1210/jc.2012-1520. Epub 2012 Jul 6.
7
Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.Aurora A 激酶抑制剂 MLN8237 治疗晚期实体瘤的 I 期研究：两种口服制剂的安全性、药代动力学、药效学和生物利用度。
Clin Cancer Res. 2012 Sep 1;18(17):4775-84. doi: 10.1158/1078-0432.CCR-12-0589. Epub 2012 Jul 5.
8
Cancer treatment and survivorship statistics, 2012.癌症治疗与生存统计，2012 年。
CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41. doi: 10.3322/caac.21149. Epub 2012 Jun 14.
9
The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis.Fbw7 和 betaTRCP E3 泛素连接酶及其在肿瘤发生中的作用。
Front Biosci (Landmark Ed). 2012 Jun 1;17(6):2197-212. doi: 10.2741/4045.
10
Aurora B kinase phosphorylates and instigates degradation of p53.极光激酶 B 使 p53 磷酸化并促使其降解。
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):E1513-22. doi: 10.1073/pnas.1110287109. Epub 2012 May 18.
Zotero 插件